Pfizer (NYSE:PFE) Trading Up 0.9%

Pfizer Inc. (NYSE:PFE) traded up 0.9% during trading on Monday . The company traded as high as $29.83 and last traded at $29.54. 4,433,478 shares were traded during mid-day trading, a decline of 88% from the average session volume of 37,923,637 shares. The stock had previously closed at $29.27.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays lifted their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Price Performance

The firm has a market cap of $169.49 billion, a P/E ratio of -496.00, a price-to-earnings-growth ratio of 1.04 and a beta of 0.68. The business has a 50-day simple moving average of $29.21 and a 200 day simple moving average of $28.13. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.62%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently made changes to their positions in the company. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer in the second quarter worth about $29,000. Quarry LP bought a new position in shares of Pfizer during the second quarter valued at approximately $31,000. Creekmur Asset Management LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $32,000. Finally, Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.